Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

Details for Australian Patent Application No. 2002327053 (hide)

International Classifications

Event Publications

23 January 2003 Complete Application Filed

Priority application(s): 60/325,360 26.09.01 US

26 June 2003 Application Open to Public Inspection

Published as AU-B-2002327053

26 June 2008 Application Accepted

Published as AU-B-2002327053

14 August 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under reg. 22.2E(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

21 August 2008 Section 223 Application Allowed

The Government of the United States, as represented by the Secretary of Health and Human Services The time in which to pay the exam response fee has been extended to 14 Aug 2008. Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden ACT 2606 2003

23 October 2008 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 22 Sep 2008. Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden ACT 2606

12 February 2009 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 22 Sep 2008

19 February 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.